trending Market Intelligence /marketintelligence/en/news-insights/trending/s2c3t3upss9UbHLxuRdbfQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Valeant making 'tangible progress towards a turnaround,' says CEO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Valeant making 'tangible progress towards a turnaround,' says CEO

Valeant Pharmaceuticals International Inc. CEO Joseph Papa said the company is delivering on its commitments and "making tangible progress towards a turnaround."

The drugmaker plans to beat its pledge to reduce $5 billion of debt from divestiture proceeds and free cash flow before February 2018, leaving the company with no significant debt maturities and no mandatory amortization requirements until 2020.

Papa said on an Aug. 8 earnings call that the company is continuing to reduce debt and resolve legacy issues.

Valeant's second-quarter adjusted net income fell to $362 million from $460 million a year ago.

The U.S. Food and Drug Administration recently rejected the company's investigative eye drops for patients with open angle glaucoma or ocular hypertension.